Open main menu

Oldest pages

Showing below up to 250 results in range #301 to #550.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Exponential survival curve‏‎ (20:01, 12 September 2019)
  2. Exposure, external or internal‏‎ (20:01, 12 September 2019)
  3. Exposure situation‏‎ (20:02, 12 September 2019)
  4. Habitual mouth breather‏‎ (12:42, 13 September 2019)
  5. Habitual nose breather‏‎ (12:42, 13 September 2019)
  6. Half-life, physical‏‎ (12:43, 13 September 2019)
  7. Hazard‏‎ (12:43, 13 September 2019)
  8. Health Surveillance‏‎ (12:43, 13 September 2019)
  9. Heliosphere‏‎ (12:44, 13 September 2019)
  10. Hierarchical tissues‏‎ (12:44, 13 September 2019)
  11. High level waste‏‎ (12:45, 13 September 2019)
  12. Hormones‏‎ (12:45, 13 September 2019)
  13. Hyperbaric oxygen‏‎ (12:46, 13 September 2019)
  14. Hypertrophic cardiomyopathy‏‎ (12:48, 13 September 2019)
  15. Hypoplasia‏‎ (12:48, 13 September 2019)
  16. Immune system‏‎ (12:49, 13 September 2019)
  17. Incident‏‎ (12:50, 13 September 2019)
  18. Inclusiveness‏‎ (12:50, 13 September 2019)
  19. Individual decontamination‏‎ (12:50, 13 September 2019)
  20. Individual monitoring‏‎ (12:51, 13 September 2019)
  21. Individual-related‏‎ (12:51, 13 September 2019)
  22. Inhalability‏‎ (12:53, 13 September 2019)
  23. Inner bremsstrahlung‏‎ (12:53, 13 September 2019)
  24. Institutional control‏‎ (12:54, 13 September 2019)
  25. Intermediate level waste‏‎ (12:54, 13 September 2019)
  26. Internal conversion electron‏‎ (12:56, 13 September 2019)
  27. Interphase death‏‎ (12:56, 13 September 2019)
  28. Intervention Level‏‎ (12:56, 13 September 2019)
  29. Interventional procedure‏‎ (12:57, 13 September 2019)
  30. Iso-effect plots‏‎ (12:58, 13 September 2019)
  31. Isomers‏‎ (12:58, 13 September 2019)
  32. Isotropic geometry‏‎ (12:58, 13 September 2019)
  33. Itinerant (radiation) worker‏‎ (12:59, 13 September 2019)
  34. Latent time/period or latency interval‏‎ (13:01, 13 September 2019)
  35. Limitation of dose‏‎ (13:01, 13 September 2019)
  36. Lineal energy‏‎ (13:02, 13 September 2019)
  37. Linear-non-threshold model‏‎ (13:03, 13 September 2019)
  38. Low level waste‏‎ (13:08, 13 September 2019)
  39. Lymphatic system‏‎ (13:08, 13 September 2019)
  40. Macrophage colony stimulating factor‏‎ (13:08, 13 September 2019)
  41. Magnetosphere‏‎ (13:09, 13 September 2019)
  42. Member of the public‏‎ (13:10, 13 September 2019)
  43. Mendelian diseases‏‎ (13:10, 13 September 2019)
  44. Mitigation‏‎ (13:10, 13 September 2019)
  45. Multistage tumorigenesis‏‎ (13:11, 13 September 2019)
  46. Myocardial perfusion‏‎ (13:12, 13 September 2019)
  47. Myocardial stress test‏‎ (13:13, 13 September 2019)
  48. Naturally occurring radioactive material‏‎ (13:14, 13 September 2019)
  49. Necrosis‏‎ (13:14, 13 September 2019)
  50. Neurological syndrome‏‎ (13:14, 13 September 2019)
  51. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  52. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  53. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  54. Particle radiance‏‎ (13:28, 13 September 2019)
  55. Peak skin dose‏‎ (13:28, 13 September 2019)
  56. Pelagic‏‎ (13:29, 13 September 2019)
  57. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  58. Pericarditis‏‎ (13:29, 13 September 2019)
  59. Pharynx‏‎ (13:30, 13 September 2019)
  60. Planned exposure situation‏‎ (13:30, 13 September 2019)
  61. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  62. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  63. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  64. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  65. Principle of justification‏‎ (13:33, 13 September 2019)
  66. Principle of optimisation‏‎ (13:33, 13 September 2019)
  67. Procedural values‏‎ (13:34, 13 September 2019)
  68. Progenitor cell‏‎ (13:35, 13 September 2019)
  69. Projected dose‏‎ (13:36, 13 September 2019)
  70. Protection strategy‏‎ (13:37, 13 September 2019)
  71. Protective action‏‎ (13:37, 13 September 2019)
  72. Protective action guide‏‎ (13:38, 13 September 2019)
  73. Public exposure‏‎ (13:39, 13 September 2019)
  74. Radiation modifier‏‎ (13:41, 13 September 2019)
  75. Radiation safety officer‏‎ (13:42, 13 September 2019)
  76. Radiation worker‏‎ (13:44, 13 September 2019)
  77. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  78. Radioactive source‏‎ (13:45, 13 September 2019)
  79. Radioactive substance‏‎ (13:46, 13 September 2019)
  80. Radioactivity‏‎ (13:46, 13 September 2019)
  81. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  82. Radiographer‏‎ (13:48, 13 September 2019)
  83. Radiological protection principles‏‎ (13:49, 13 September 2019)
  84. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  85. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  86. Radiosensitiser‏‎ (13:50, 13 September 2019)
  87. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  88. Reasonableness‏‎ (13:50, 13 September 2019)
  89. Recovery‏‎ (13:51, 13 September 2019)
  90. Recovery responder‏‎ (13:51, 13 September 2019)
  91. Reference bioassay function‏‎ (13:51, 13 September 2019)
  92. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  93. Reference level‏‎ (13:52, 13 September 2019)
  94. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  95. Relocation‏‎ (13:53, 13 September 2019)
  96. Remedial action‏‎ (13:53, 13 September 2019)
  97. Remediation‏‎ (13:53, 13 September 2019)
  98. Repopulation‏‎ (13:54, 13 September 2019)
  99. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  100. Representative person‏‎ (13:54, 13 September 2019)
  101. Reproductive integrity‏‎ (13:55, 13 September 2019)
  102. Residual dose‏‎ (13:55, 13 September 2019)
  103. Respiratory protection‏‎ (13:55, 13 September 2019)
  104. Retrievability‏‎ (13:56, 13 September 2019)
  105. Reversibility‏‎ (13:56, 13 September 2019)
  106. Right to know‏‎ (13:57, 13 September 2019)
  107. Rigidity‏‎ (13:58, 13 September 2019)
  108. Routine monitoring‏‎ (13:58, 13 September 2019)
  109. Safety case‏‎ (13:59, 13 September 2019)
  110. Safety culture‏‎ (13:59, 13 September 2019)
  111. Scintigraphy‏‎ (13:59, 13 September 2019)
  112. Self-help protection‏‎ (14:00, 13 September 2019)
  113. Slow repair‏‎ (14:01, 13 September 2019)
  114. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  115. Solar cycle‏‎ (14:01, 13 September 2019)
  116. Solar particle event‏‎ (14:01, 13 September 2019)
  117. Source term‏‎ (14:02, 13 September 2019)
  118. Source-related‏‎ (14:02, 13 September 2019)
  119. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  120. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  121. Spontaneous fission‏‎ (14:03, 13 September 2019)
  122. Stakeholder‏‎ (14:04, 13 September 2019)
  123. Stenosis‏‎ (14:04, 13 September 2019)
  124. Storage‏‎ (14:04, 13 September 2019)
  125. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  126. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  127. Systemic model‏‎ (14:06, 13 September 2019)
  128. Tachycardia‏‎ (14:10, 13 September 2019)
  129. Target region‏‎ (14:10, 13 September 2019)
  130. Target tissue‏‎ (14:10, 13 September 2019)
  131. Telangiectasia‏‎ (14:11, 13 September 2019)
  132. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  133. Thyroid blocking‏‎ (14:11, 13 September 2019)
  134. Time factor‏‎ (14:11, 13 September 2019)
  135. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  136. Tolerability‏‎ (14:12, 13 September 2019)
  137. Track structure‏‎ (14:13, 13 September 2019)
  138. Transfer compartment‏‎ (14:14, 13 September 2019)
  139. Transfer rate‏‎ (14:14, 13 September 2019)
  140. Transforming growth factor‏‎ (14:15, 13 September 2019)
  141. Transparency‏‎ (14:15, 13 September 2019)
  142. Trapped particles‏‎ (14:16, 13 September 2019)
  143. Types of materials‏‎ (14:16, 13 September 2019)
  144. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  145. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  146. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  147. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  148. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  149. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  150. ICRPædia Guides‏‎ (18:33, 9 October 2019)
  151. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (13:57, 17 October 2019)
  152. Guide to Radiological Protection in Healthcare‏‎ (13:59, 17 October 2019)
  153. The System of Radiological Protection‏‎ (15:15, 23 October 2019)
  154. Quotes from Publications on the System of Radiological Protection‏‎ (17:58, 23 October 2019)
  155. Guide to the System of Radiological Protection‏‎ (15:40, 24 October 2019)
  156. General Information on Radon‏‎ (12:41, 30 October 2019)
  157. System Of Radiation Protection Overview‏‎ (15:02, 4 November 2019)
  158. System of radiation protection module 2‏‎ (15:11, 4 November 2019)
  159. Absorbed, Equivalent, and Effective Dose‏‎ (21:54, 21 November 2019)
  160. Radon For Governments and Employers‏‎ (18:19, 3 December 2019)
  161. Radon For Homeowners and Residents‏‎ (18:19, 3 December 2019)
  162. Guide to Radon‏‎ (07:37, 5 February 2020)
  163. Main Page‏‎ (12:31, 18 November 2020)
  164. Additive risk projection model‏‎ (20:28, 24 February 2021)
  165. Attributable risk‏‎ (20:30, 24 February 2021)
  166. Dicentric chromosome‏‎ (20:31, 24 February 2021)
  167. Effect modifier‏‎ (20:32, 24 February 2021)
  168. Hereditary effect‏‎ (20:33, 24 February 2021)
  169. Low dose‏‎ (20:33, 24 February 2021)
  170. Low dose rate‏‎ (20:35, 24 February 2021)
  171. Multiplicative risk projection model‏‎ (20:36, 24 February 2021)
  172. Ring chromosome‏‎ (20:38, 24 February 2021)
  173. Severe deterministic injury‏‎ (20:38, 24 February 2021)
  174. Somatic effect‏‎ (20:39, 24 February 2021)
  175. Transgenerational effect‏‎ (20:40, 24 February 2021)
  176. Detriment-adjusted risk‏‎ (20:42, 24 February 2021)
  177. Elemental dose‏‎ (20:44, 24 February 2021)
  178. Multistage carcinogenesis model‏‎ (20:50, 24 February 2021)
  179. Mutation component‏‎ (20:51, 24 February 2021)
  180. Oncogene‏‎ (20:52, 24 February 2021)
  181. Population risk‏‎ (20:53, 24 February 2021)
  182. Potentially lethal damage repair‏‎ (20:54, 24 February 2021)
  183. Radiation risk‏‎ (20:55, 24 February 2021)
  184. Relative life lost‏‎ (20:56, 24 February 2021)
  185. Risk model‏‎ (20:57, 24 February 2021)
  186. Sublethal damage repair‏‎ (20:58, 24 February 2021)
  187. Transfer of risk‏‎ (20:59, 24 February 2021)
  188. Tumour suppressor gene‏‎ (21:00, 24 February 2021)
  189. Acute radiation syndrome‏‎ (21:40, 24 February 2021)
  190. Adaptive response‏‎ (21:42, 24 February 2021)
  191. Α/β value‏‎ (21:46, 24 February 2021)
  192. ΓH2AX foci‏‎ (21:46, 24 February 2021)
  193. Informed consent‏‎ (21:49, 24 February 2021)
  194. Supervised area‏‎ (21:51, 24 February 2021)
  195. Access control‏‎ (21:52, 24 February 2021)
  196. Acute exposure‏‎ (21:54, 24 February 2021)
  197. Adventitious source‏‎ (21:55, 24 February 2021)
  198. Authorised discharge‏‎ (21:57, 24 February 2021)
  199. Backscatter factor‏‎ (21:59, 24 February 2021)
  200. Best available techniques‏‎ (22:00, 24 February 2021)
  201. Disposal facility‏‎ (22:02, 24 February 2021)
  202. Dose modifying factor‏‎ (22:03, 24 February 2021)
  203. Exposure pathway‏‎ (22:05, 24 February 2021)
  204. Radiological controlled area‏‎ (22:07, 24 February 2021)
  205. Life Span Study‏‎ (22:10, 24 February 2021)
  206. Detriment‏‎ (19:17, 25 February 2021)
  207. Baseline disease rates‏‎ (19:29, 25 February 2021)
  208. Biomarker‏‎ (19:31, 25 February 2021)
  209. Case–control study‏‎ (19:33, 25 February 2021)
  210. Deterministic effect‏‎ (19:38, 25 February 2021)
  211. Dose and dose-rate effectiveness factor‏‎ (15:54, 26 February 2021)
  212. Dose-threshold hypothesis‏‎ (15:56, 26 February 2021)
  213. Tissue reaction‏‎ (16:00, 26 February 2021)
  214. Doubling dose‏‎ (17:10, 26 February 2021)
  215. Epigenetic effects‏‎ (17:13, 26 February 2021)
  216. Excess absolute risk‏‎ (17:16, 26 February 2021)
  217. Excess relative risk‏‎ (17:25, 26 February 2021)
  218. Homologous recombination‏‎ (17:26, 26 February 2021)
  219. Incidence‏‎ (17:28, 26 February 2021)
  220. Induced genomic instability‏‎ (17:30, 26 February 2021)
  221. Late normal tissue responses‏‎ (17:31, 26 February 2021)
  222. LD 50/30‏‎ (17:33, 26 February 2021)
  223. Lifetime risk estimates‏‎ (17:42, 26 February 2021)
  224. Linear dose response‏‎ (17:43, 26 February 2021)
  225. Linear-quadratic dose response model‏‎ (17:48, 26 February 2021)
  226. Stochastic effect‏‎ (17:58, 26 February 2021)
  227. Nominal risk coefficient‏‎ (19:29, 26 February 2021)
  228. Non-homologous end joining‏‎ (19:30, 26 February 2021)
  229. Non-targeted effects‏‎ (19:31, 26 February 2021)
  230. Normal tissue complication probability‏‎ (19:33, 26 February 2021)
  231. Pooled analysis‏‎ (19:34, 26 February 2021)
  232. Quasi-threshold dose‏‎ (19:35, 26 February 2021)
  233. Reactive oxygen species‏‎ (19:36, 26 February 2021)
  234. Recovery (cellular or tissue)‏‎ (19:38, 26 February 2021)
  235. Reference Animal and Plant‏‎ (19:43, 26 February 2021)
  236. Relative biological effectiveness‏‎ (20:22, 26 February 2021)
  237. Relative risk‏‎ (20:25, 26 February 2021)
  238. Risk coefficient‏‎ (20:30, 26 February 2021)
  239. Targeted effects‏‎ (20:32, 26 February 2021)
  240. Translocation‏‎ (20:33, 26 February 2021)
  241. Radiation source‏‎ (21:04, 26 February 2021)
  242. Dose-response function‏‎ (14:57, 28 March 2021)
  243. Tissue weighting factor‏‎ (21:32, 28 March 2021)
  244. Absorption‏‎ (22:15, 28 March 2021)
  245. Activation‏‎ (22:16, 28 March 2021)
  246. Activity‏‎ (22:19, 28 March 2021)
  247. ICRPædia Guide to the System of Radiological Protection‏‎ (21:44, 3 May 2021)
  248. Active detection system‏‎ (19:35, 11 August 2021)
  249. Additional dose‏‎ (19:36, 11 August 2021)
  250. Allometry‏‎ (19:37, 11 August 2021)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)